Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043070 | 1.00 | OPRL1 (0.39) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL731280 | 1.00 | OPRL1 (0.39) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL872075 | 1.00 | OPRL1 (0.39) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL872074 | 1.00 | OPRL1 (0.39) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL10043091 | 0.99 | OPRL1 (0.39) | OPRL1CYP2C9MAPTGAASPHK1 | |
| SCHEMBL10043090 | 0.96 | OPRL1 (0.41) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL10043499 | 0.96 | OPRL1 (0.41) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL10043509 | 0.95 | OPRL1 (0.41) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL10043092 | 0.95 | OPRL1 (0.41) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL10043433 | 0.95 | OPRL1 (0.41) | OPRL1CYP2C9MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470199-B2 | Five-ring liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120074355-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | HTR3D, KIF23, CCND3 | OPRL1 2105/4885CYP2C9 3544/4885MAPT 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.